Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 AML Highlights
31 January 2025 | Virtual Webinar
Post-ASH 2024 AML Highlights
Featuring presentations & discussions on selected AML abstracts from the 66th ASH Annual Meeting and Exposition
Friday 31 January | 09:00 – 11:30 CST/ 15:00 – 17:30 GMT/ 16:00 – 18:30 CET
Chair: Naval Daver | Moderators: Charlie Craddock, Jessica Altman, and Marion Subklewe
The Post-ASH 2024 AML Highlights was supported by Genentech and Sumitomo Pharma. Supporters have no influence over the production of content.
Explore all presentations and discussions below:
Session 1: Latest findings from translational science in AML
Single-cell multi-omic analysis of KMT2A-rearranged pediatric acute leukemia clonal evolution
Linde Miles University of Cincinnati, Cincinnati, OH, United States
Clonal basis of resistance and response to ivosidenib combination therapies is established early during treatment in IDH1-mutated myeloid malignancies
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacitidine and venetoclax for newly diagnosed AML
Tapan Kadia The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Session 2: Novel approaches to chemotherapy and BCL-2 inhibition
Venetoclax combined with 7+3 induction chemotherapy induces high MRD-negative response rates in newly diagnosed AML patients fit for intensive chemotherapy across ages
Ioannis Mantzaris Montefiore Medical Center, New York City, NY, United States
A randomized comparison of CPX-351 and FLAG-Ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial
Priyanka Mehta University Hospitals of Bristol and Weston NHS Trust, Bristol, United Kingdom
Influence of AML differentiation state in risk stratification of frontline therapy with hypomethylating agents + venetoclax in AML
Curtis Lachowiez University of Texas MD Anderson Cancer Center, Houston, TX, United States
A Phase II randomized trial comparing low-dose cytarabine and venetoclax +/- midostaurin in non-adverse cytogenetic risk AML: the ALLG AMLM25 Intervene trial
Chong Chyn Chua Alfred Hospital and Monash University, Melbourne, Australia
Panel discussion
Session 3: Advances with menin inhibitors and bispecifics
Bleximenib dose optimization and determination of RP2D from a Phase I study in R/R acute leukemia patients with KMT2A and NPM1 alterations
Emma Searle The Christie NHS Foundation Trust, Manchester, United Kingdom
Phase I results: first-in-human Phase I/II study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with R/R acute leukemia
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
Phase I/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in R/R AML
Ghayas Issa The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Updated results and longer follow-up from the AUGMENT-101 Phase II study of revumenib in all patients with R/R KMT2Ar acute leukemia
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r AML: interim Phase Ia results from KOMET-007
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Panel discussion
Session 4: Predicting and assessing treatment response in FLT3-mutated AML
Characteristics and outcomes of patients with AML and FLT3-TKD mutations
Sankalp Arora University of Texas MD Anderson Cancer Center, Houston, TX, United States
Correlation of baseline gene mutations with quizartinib efficacy in patients with FLT3-ITD positive newly diagnosed AML in the Phase III QuANTUM-First trial
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
Enhanced validation of the FLT3-like gene expression signature as a predictive biomarker for quizartinib response in FLT3-ITD negative AML: expanded cohort and extended follow-up from the Pethema Quiwi trial
Adrián Mosquera Orgueira University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Gilteritinib results in higher remission and transplant rates than midostaurin but does not increase the post-induction mutational MRD negative rate: results of the Phase II randomized Precog 0905 study in newly diagnosed FLT3 mutated AML
Selina Luger University of Pennsylvania, Philadelphia, PA, United States
Long-term survival outcomes and cytogenetic/molecular patterns of relapse in adults with FLT3-mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 5: Real-world evidence for AML diagnosis, treatment and outcomes
Challenges in leukemia diagnosis and treatment in Mexico: a survey by the alliance for leukemias in Mexico on resource availability, infrastructure, and access to advanced therapies for leukemia patients
Roberta Demichelis University of Texas MD Anderson Cancer Center, Houston, TX, United States
No differences in transplant outcomes with post-transplant cyclophosphamide in one antigen mismatched unrelated donor compared to matched unrelated donor recipients receiving antithymocyte globulin in patients with AML: a study from the Acute Leukemia Working Party of the EBMT
Giorgia Battipaglia Federico II University of Naples, Naples, Italy
Panel discussion
